ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, Valletta’s team successfully restored the protein expression of ASXL1 and significantly prolonged the survival rate of mice by correcting the nonsense mutation of ASXL1 in chronic myeloid leukemia (Valletta et al., 2015), which not only verified the preclinical feasibility of driving gene repair but also revealed the deep mechanism of gene editing to reverse the malignant process of tumors.